临床研究
Copyright ©The Author(s) 2025.
世界华人消化杂志. 2025-03-28; 33(3): 192-198
在线出版 2025-03-28. doi: 10.11569/wcjd.v33.i3.192
表1 两组一般资料、血清25(OH)D3、PTX3水平比较[(mean±SD)/n(%)]
组别n性别(男/女)年龄(岁)体重指数(kg/m2)吸烟心率(次/min)平均动脉压(mmHg)空腹血糖(mmol/L)总胆固醇(mmol/L)三酰甘油(mmol/L)25(OH)D3(ng/mL)PTX3(ng/mL)
研究组12070/5056.12±8.4323.65±1.8431(25.83)78.65±5.2790.53±8.296.61±0.825.13±1.402.13±0.7822.58±5.62b0.61±0.19b
对照组12065/5554.86±8.1923.29±1.9125(20.83)77.82±6.1388.91±8.546.43±0.764.82±1.331.96±0.6535.16±7.140.27±0.08
χ2/t0.4231.1741.4870.8391.1251.4911.7641.7591.83415.16618.067
P0.5150.2410.1380.3600.2620.1370.0790.0800.068<0.01<0.01
表2 不同肝脂肪含量患者血清25(OH)D3、PTX3水平比较(mean±SD)
肝脂肪含量n25(OH)D3(ng/mL)PTX3(ng/mL)
5%-33%6126.15±5.180.48±0.15
34%-66%3720.43±4.26b0.69±0.18b
>66%2216.30±3.77bd0.84±0.21bd
F41.47341.319
P<0.01<0.01
表3 血清25(OH)D3、PTX3水平与NAFLD患者肝脂肪含量的相关性
指标25(OH)D3PTX3
肝脂肪含量r-0.7160.695
P<0.01<0.01
表4 不同肝纤维化程度患者血清25(OH)D3、PTX3、肝纤维化及肝功能指标水平比较(mean±SD)
肝纤维化程度n25(OH)D3(ng/mL)PTX3(ng/mL)HA(μg/L)PCⅢ(μg/L)PCⅣ(μg/L)ALT(U/L)AST(U/L)
肝纤维化4217.49±3.85b0.79±0.19b115.26±35.39b143.75±45.28b88.61±25.37b54.61±8.39b83.24±10.53b
无肝纤维化7825.32±4.970.51±0.1676.53±22.86107.54±31.0262.96±20.1537.26±8.7172.18±8.65
t8.8718.5547.2645.1686.06310.5416.183
P<0.01<0.01<0.01<0.01<0.01<0.01<0.01
表5 血清25(OH)D3、PTX3水平与肝纤维化及肝功能指标的相关性
指标HAPCⅢPCⅣALTAST
25(OH)D3r-0.618-0.503-0.577-0.653-0.586
P<0.01<0.01<0.01<0.01<0.01
PTX3r0.5940.4870.5410.6220.559
P<0.010.0050.001<0.01<0.01
表6 血清25(OH)D3、PTX3诊断肝纤维化的价值
指标AUC95%CI截断值敏感度(%)特异度(%)P
25(OH)D30.7130.623-0.79220.15 ng/mL88.1048.72<0.01
PTX30.7810.697-0.8520.70 ng/mL83.3167.95<0.01
25(OH)D3联合PTX30.9080.842-0.953-85.7183.33<0.01
肝纤维化指标联合0.9150.867-0.971-87.1282.09<0.01

引文著录: 戴简吉, 邓旖, 王国峰, 林开勤, 何建荣, 胡晓钢. 血清25(OH)D3、PTX3与NAFLD患者肝脂肪含量的关系及对肝纤维化的诊断价值分析. 世界华人消化杂志 2025; 33(3): 192-198